UK markets close in 3 hours 18 minutes
  • FTSE 100

    7,113.03
    -10.83 (-0.15%)
     
  • FTSE 250

    23,442.36
    +94.63 (+0.41%)
     
  • AIM

    1,257.50
    -1.38 (-0.11%)
     
  • GBP/EUR

    1.1752
    +0.0022 (+0.19%)
     
  • GBP/USD

    1.3931
    +0.0046 (+0.33%)
     
  • BTC-GBP

    27,356.32
    -335.45 (-1.21%)
     
  • CMC Crypto 200

    945.57
    +18.80 (+2.03%)
     
  • S&P 500

    4,402.66
    -20.49 (-0.46%)
     
  • DOW

    34,792.67
    -323.73 (-0.92%)
     
  • CRUDE OIL

    68.00
    -0.15 (-0.22%)
     
  • GOLD FUTURES

    1,816.00
    +1.50 (+0.08%)
     
  • NIKKEI 225

    27,728.12
    +144.04 (+0.52%)
     
  • HANG SENG

    26,204.69
    -221.86 (-0.84%)
     
  • DAX

    15,696.74
    +4.61 (+0.03%)
     
  • CAC 40

    6,762.97
    +16.74 (+0.25%)
     

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 23 June 2021 at 15.30 EEST

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly or indirectly by BlackRock, Inc and its funds decreased on 22 June 2021 below five (5) per cent of Orion Corporation’s total shares.

Total positions of BlackRock, Inc and its funds subject to notification:

% of shares and voting rights
(total of point A)

% of shares and voting rights through financial instruments
(total of point B)

Total of both in % (points A + B)

Total number of shares and voting rights of issuer

Resulting situation on the date on which threshold was crossed or reached

4.94% shares



Below 5% voting rights

0.07% shares



Below 5% voting rights

5.01% shares



Below 5% voting rights

141,134,278 shares



806,883,011 voting rights

Position of previous notification (if applicable)

5.00% shares



Below 5% voting rights

0.07% shares



Below 5% voting rights

5.08% shares



Below 5% voting rights

Notified details of the resulting situation on the date on which the threshold was crossed:

Point A: Shares and voting rights:

Class/type of shares
ISIN code

Number of shares and voting rights

% of shares and voting rights

Direct (SMA 9:5)

Indirect (SMA 9:6 and 9:7)

Direct (SMA 9:5)

Indirect (SMA 9:6 and 9:7)

FI0009014377

6,977,726 shares



Below 5% voting rights

4.94% shares



Below 5% voting rights

POINT A SUBTOTAL

6,977,726 shares



Below 5% voting rights

4.94% shares



Below 5% voting rights

Point B: Financial instruments according to SMA 9:6a:

Type of financial instrument

Expiration date

Exercise / Conversion Period

Physical or cash settlement

Number of shares and voting rights

% of shares and voting rights

Securities Lent

N/A

N/A

Physical

68,586 shares

0.04% shares

CFD

N/A

N/A

Cash

35,888 shares



Below 5% voting rights

0.02% shares



Below 5% voting rights

POINT B SUBTOTAL

104,474 shares



Below 5% voting rights

0.07% shares



Below 5% voting rights

Orion Corporation

Timo Lappalainen

President and CEO

Olli Huotari

SVP, Corporate Functions


Contact person:
Tuukka Hirvonen, Investor Relations, Orion Corporation
tel. +358 10 426 2721

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2020 amounted to EUR 1,078 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting